Literature DB >> 15931286

Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.

Michael E Spieth1, Steven B Standiford, Marjorie E Starkman, John Gough.   

Abstract

A novel approach to locating and surgically resecting occult metastatic foci in a 25-year-old female with a history of total thyroidectomy for differentiated thyroid carcinoma was attempted. Two iodine-131 (131I) body scans were performed: one after the patient underwent a 2-3 week thyroxine withdrawal, and another the following week utilizing recombinant TSH-stimulation. Then the patient was treated with 151 mCi of 131I, and 2 weeks later, without further hormonal manipulation, she had radioguided surgery. The two diagnostic 131I body scans were negative, but the post-therapy scan was positive. Two weeks later after pre-operative skin marking, radioguided surgery localized metastatic foci in the central compartment neck just dorsal to the suprasternal notch. No other foci were identified with the probe at surgery. At pathology, 2 of the 12 nodes were positive, as well as a 1 mm metastatic focus in the fat. Provocative imaging protocols, aggressive radioiodine therapy, and the novel use of radioguided surgery to attempt a cure in an 131I image-negative metastatic thyroid carcinoma patient was performed. No other cases using these combined diagnostic and therapeutic efforts have been reported in the literature.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15931286      PMCID: PMC1069022          DOI: 10.3121/cmr.1.1.53

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  39 in total

1.  Characteristics of thyroid carcinomas in aging patients.

Authors:  J D Lin; T C Chao; S T Chen; H F Weng; K D Lin
Journal:  Eur J Clin Invest       Date:  2000-02       Impact factor: 4.686

Review 2.  Two cases of medullary thyroid carcinoma.

Authors:  M Jong; F X Sundram
Journal:  Ann Acad Med Singapore       Date:  2001-11       Impact factor: 2.473

3.  Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.

Authors:  F Pacini; E Molinaro; F Lippi; M G Castagna; L Agate; C Ceccarelli; D Taddei; R Elisei; M Capezzone; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

4.  Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.

Authors:  F Moog; R Linke; N Manthey; R Tiling; P Knesewitsch; K Tatsch; K Hahn
Journal:  J Nucl Med       Date:  2000-12       Impact factor: 10.057

5.  Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?

Authors:  V Fatourechi; I D Hay; B P Mullan; G A Wiseman; G Z Eghbali-Fatourechi; L M Thorson; C A Gorman
Journal:  Thyroid       Date:  2000-07       Impact factor: 6.568

6.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin.

Authors:  R J Robbins; R M Tuttle; M Sonenberg; A Shaha; R Sharaf; H Robbins; M Fleisher; S M Larson
Journal:  Thyroid       Date:  2001-09       Impact factor: 6.568

7.  Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.

Authors:  M A Muros; J M Llamas-Elvira; A Ramírez-Navarro; M J Gómez; A Rodríguez-Fernández; T Muros; M López de la Torre; A Becerra; J L Carreras
Journal:  Am J Surg       Date:  2000-06       Impact factor: 2.565

8.  [Clinical value of 99mTc-MIBI imaging, 131I whole body scan and HTG determination for the follow-up of patients with differentiated thyroid carcinoma after 131I therapy].

Authors:  N Yu; C Guan; Y Liu; X Yang
Journal:  Hua Xi Yi Ke Da Xue Xue Bao       Date:  1999-12

9.  Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.

Authors:  A David; A Blotta; M Bondanelli; R Rossi; E Roti; L E Braverman; L Busutti; E C degli Uberti
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

10.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.

Authors:  U Feine; R Lietzenmayer; J P Hanke; J Held; H Wöhrle; W Müller-Schauenburg
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.